Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Experimental biological therapy is a dual antagonist of interleukin-1α and interleukin-1β.
Main Inclusion Criteria: Patients over 18 years old who, with or after adalimumab therapy (biological therapy), exhibit symptoms consistent with moderate to severe hidradenitis suppurativa.
Status: In preparation
Start of Patient Enrollment: December 2024